Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402899> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4308402899 abstract "<h3>Background</h3> Trastuzumab (Tras) monoclonal antibody targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). FDA approved Tras for the treatment of HER2 positive breast cancer. Cholangiocarcinoma (CCA) is a cancer forms in the bile ducts. Several CCAs are multifocal and cannot be completely removed by surgery and are incurable. Combination of gemcitabine and cisplatin is a standard first line therapy for patients with advanced CCA. Nowadays, the precision medicine and immunotherapy has been playing remarkable roles for cancer treatment. In this study, we found that HER2 expression is relatively high in CCA PDX and cell lines from Thailand. We hypothesized and speculated that Trastuzumab could be a promising antibody immunotherapy for CCAs. <h3>Methods</h3> We examined surface HER2 expression on 5 CCA cell lines (M213B, D068, D113, RBE, YSCCC) and patient-derived cell (PDC) by Flowcytometry. We defined the activities of antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP) by using FcR-bearing recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements. ADCC was then confirmed by using CD16-transduced NK cell line (KHYG-1) and NK cells from a healthy donor. Rabbit and human serum were administered to test CDC activity of Tras. To clarify ADCP activity, we used mouse peritoneal macrophages and monocyte-derived macrophages from healthy donor as effector cells. Moreover, we performed MTT assay to investigate the direct effect of Tras. Finally, we evaluated the efficacy of Tras <i>in vivo</i> xenograft and PDX model. <h3>Results</h3> Flowcytometric analysis and immunohistochemistry revealed high expression of HER2 in CCA cells. Tras conferred ADCC, ADCP, CDC, and direct effect to induce CCA cell death. Tras demonstrated potent <i>in vivo</i> inhibitory effect using PDX model. <h3>Conclusions</h3> <h3>Tras indicates multi-activities against CCA. </h3> Tras can be considered as a promising antibody immunotherapy for the treatment of HER2 expressing CCA. <h3>Ethics Approval</h3> The use of human materials is approved by Kumamoto University9s ethical committee (ID: 30-78-20-20201119). Animal experiments are approved by Kumamoto Univeristy9s animal ethics committee (ID: A2021-053)" @default.
- W4308402899 created "2022-11-11" @default.
- W4308402899 creator A5045233854 @default.
- W4308402899 creator A5060855417 @default.
- W4308402899 date "2022-11-01" @default.
- W4308402899 modified "2023-09-25" @default.
- W4308402899 title "846 Trastuzumab, an anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma (CCA) via multiple mechanisms" @default.
- W4308402899 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0846" @default.
- W4308402899 hasPublicationYear "2022" @default.
- W4308402899 type Work @default.
- W4308402899 citedByCount "0" @default.
- W4308402899 crossrefType "proceedings-article" @default.
- W4308402899 hasAuthorship W4308402899A5045233854 @default.
- W4308402899 hasAuthorship W4308402899A5060855417 @default.
- W4308402899 hasBestOaLocation W43084028991 @default.
- W4308402899 hasConcept C109316439 @default.
- W4308402899 hasConcept C121608353 @default.
- W4308402899 hasConcept C126322002 @default.
- W4308402899 hasConcept C159654299 @default.
- W4308402899 hasConcept C185592680 @default.
- W4308402899 hasConcept C202751555 @default.
- W4308402899 hasConcept C203014093 @default.
- W4308402899 hasConcept C2777701055 @default.
- W4308402899 hasConcept C2779786085 @default.
- W4308402899 hasConcept C2780258809 @default.
- W4308402899 hasConcept C40677261 @default.
- W4308402899 hasConcept C502942594 @default.
- W4308402899 hasConcept C530470458 @default.
- W4308402899 hasConcept C542903549 @default.
- W4308402899 hasConcept C54355233 @default.
- W4308402899 hasConcept C55493867 @default.
- W4308402899 hasConcept C71924100 @default.
- W4308402899 hasConcept C81885089 @default.
- W4308402899 hasConcept C86803240 @default.
- W4308402899 hasConceptScore W4308402899C109316439 @default.
- W4308402899 hasConceptScore W4308402899C121608353 @default.
- W4308402899 hasConceptScore W4308402899C126322002 @default.
- W4308402899 hasConceptScore W4308402899C159654299 @default.
- W4308402899 hasConceptScore W4308402899C185592680 @default.
- W4308402899 hasConceptScore W4308402899C202751555 @default.
- W4308402899 hasConceptScore W4308402899C203014093 @default.
- W4308402899 hasConceptScore W4308402899C2777701055 @default.
- W4308402899 hasConceptScore W4308402899C2779786085 @default.
- W4308402899 hasConceptScore W4308402899C2780258809 @default.
- W4308402899 hasConceptScore W4308402899C40677261 @default.
- W4308402899 hasConceptScore W4308402899C502942594 @default.
- W4308402899 hasConceptScore W4308402899C530470458 @default.
- W4308402899 hasConceptScore W4308402899C542903549 @default.
- W4308402899 hasConceptScore W4308402899C54355233 @default.
- W4308402899 hasConceptScore W4308402899C55493867 @default.
- W4308402899 hasConceptScore W4308402899C71924100 @default.
- W4308402899 hasConceptScore W4308402899C81885089 @default.
- W4308402899 hasConceptScore W4308402899C86803240 @default.
- W4308402899 hasLocation W43084028991 @default.
- W4308402899 hasOpenAccess W4308402899 @default.
- W4308402899 hasPrimaryLocation W43084028991 @default.
- W4308402899 hasRelatedWork W1673659691 @default.
- W4308402899 hasRelatedWork W1967470546 @default.
- W4308402899 hasRelatedWork W1997275703 @default.
- W4308402899 hasRelatedWork W2042242992 @default.
- W4308402899 hasRelatedWork W2061223989 @default.
- W4308402899 hasRelatedWork W2067077431 @default.
- W4308402899 hasRelatedWork W2094936714 @default.
- W4308402899 hasRelatedWork W2122854061 @default.
- W4308402899 hasRelatedWork W2417631503 @default.
- W4308402899 hasRelatedWork W2443772760 @default.
- W4308402899 isParatext "false" @default.
- W4308402899 isRetracted "false" @default.
- W4308402899 workType "article" @default.